Full video transcriptClick to expand
Auto-generated transcript of @tiff.mj.journey's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:01That it's true
- 0:06Me and my money attacks, emotional me, I get a clutch and if you get too close
100 pounds lost on semaglutide: what the scale won't tell you
Quick answer
The video documents a claimed 100-pound weight loss attributed to a GLP-1 receptor agonist (implied semaglutide via #zempic hashtag), with the creator reporting no regrets about the experience. No clinical details are provided: no dosing, duration, comorbidities, or side effect history. Given that the STEP 1 trial (Wilding et al., 2021, NEJM) documented average losses of approximately 15% body weight on semaglutide 2.4mg, a 100-pound loss would be achievable but toward the upper end of reported outcomes and would likely require extended treatment duration and medical oversight.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For 100 pounds lost on semaglutide: what the scale won't tell you, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "100 pounds lost on semaglutide: what the scale won't tell you" from Tiff | MJ Journey. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video documents a claimed 100-pound weight loss attributed to a GLP-1 receptor agonist (implied semaglutide via hashtag), with the creator reporting no regrets about the experience.
The reason this review is not generic is the source wording and the canonical claim label "glp1 any regrets nope motivation healthylifestyle transformation." In this clip, the useful excerpt is: "That it's true Me and my money attacks, emotional me, I get a clutch and if you get too close" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video documents a claimed 100-pound weight loss attributed to a GLP-1 receptor agonist (implied semaglutide via hashtag), with the creator reporting no regrets about the experience.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video documents a claimed 100-pound weight loss attributed to a GLP-1 receptor agonist (implied semaglutide via #zempic hashtag), with the creator reporting no regrets about the experience. No clinical details are provided: no dosing, duration, comorbidities, or side effect history. Given that the STEP 1 trial (Wilding et al., 2021, NEJM) documented average losses of approximately 15% body weight on semaglutide 2.4mg, a 100-pound loss would be achievable but toward the upper end of reported outcomes and would likely require extended treatment duration and medical oversight.
- STEP 1 trial data (Wilding et al., 2021, NEJM): average weight loss on semaglutide 2.4mg was 14.9% over 68 weeks, making a 100-pound loss possible but above average.
- More than 70% of semaglutide users in clinical trials reported gastrointestinal side effects including nausea, vomiting, and diarrhea (Davies et al., 2021, Lancet).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- STEP 1 trial data (Wilding et al., 2021, NEJM): average weight loss on semaglutide 2.4mg was 14.9% over 68 weeks, making a 100-pound loss possible but above average.
- More than 70% of semaglutide users in clinical trials reported gastrointestinal side effects including nausea, vomiting, and diarrhea (Davies et al., 2021, Lancet).
- Weight regain after stopping semaglutide averages about two-thirds of lost weight within one year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
- Ozempic (semaglutide 0.5mg-2mg) is FDA-approved for type 2 diabetes. Wegovy (semaglutide 2.4mg) is the approved formulation for chronic weight management. These are not interchangeable.
- Compounded semaglutide products are not FDA-approved and have not been shown to be equivalent in safety or efficacy to brand-name Ozempic or Wegovy.
- Transformation videos on TikTok disproportionately represent positive outcomes. Survivorship bias means users with poor experiences, hospitalizations, or regain are less likely to post at 464,000 views.
- GLP-1 agonists carry a boxed FDA warning regarding thyroid C-cell tumor risk observed in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma should not use these drugs.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @tiff.mj.journey actually say?
Honestly, not much, at least verbally. The transcript captured what sounds like song lyrics or background audio: "That it's true Me and my money attacks, emotional me, I get a clutch and if you get too close." That is not a medical claim. The real content here is in the visuals and the hashtags, specifically #zempic and #100gone, which together tell the story: this person used a GLP-1 receptor agonist (likely semaglutide, given the Ozempic-derived hashtag) and lost 100 pounds. The caption adds "Any regrets? Nope!" which is the actual assertion being made. She is claiming the experience was worth it, full stop. No side effects mentioned, no caveats, no timeline given. That is where the fact-check lives.
This kind of transformation video is enormously influential. At 464,600 views, a lot of people are making decisions based on the vibe here, and the vibe is unambiguously positive and regret-free.
Does the science back this up?
On the core claim, that GLP-1 agonists can produce substantial, meaningful weight loss, yes, the science is genuinely strong. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. That is not a rounding error. For someone starting at, say, 300 pounds, 100 pounds lost is not outside the range of what these drugs can do, though it would sit at the higher end of outcomes and likely required sustained use over a year or more.
The "no regrets" framing is harder to evaluate with data. The STEP trials did document meaningful side effects in a significant portion of participants. Gastrointestinal adverse events, nausea, vomiting, diarrhea, constipation, were reported in over 70% of semaglutide users (Davies et al., 2021, Lancet). The fact that this creator personally has no regrets is valid as lived experience, but it should not be read as a representative outcome.
What did they get wrong (or right)?
She did not get anything factually wrong because she did not make a factual claim. The risk here is what she left out. Showing a dramatic transformation under the hashtag #zempic with zero mention of side effects, cost, access barriers, or the need for medical supervision is a significant omission. That omission does real harm when viewers conclude GLP-1s are a smooth, consequence-free ride.
To her credit, she is not selling anything in this clip, not pushing a discount code, not claiming a cure for diabetes or obesity. She is sharing a personal outcome, which is her right. But the framing, "any regrets? nope," erases the experience of people who did have regrets: pancreatitis hospitalizations, severe GI complications, muscle mass loss, or the rebound weight gain documented after discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism). Those outcomes are real and deserve airtime too.
What should you actually know?
If you are considering a GLP-1 agonist after watching a video like this, here is what the evidence actually says. First, these drugs work. The weight loss data is among the strongest in obesity pharmacotherapy in decades. Second, they come with a real side effect profile that is not minor for everyone. Third, outcomes vary enormously based on dose, adherence, diet, baseline health status, and how long you stay on the medication.
The "#zempic" hashtag refers to Ozempic, which is semaglutide approved for type 2 diabetes. Wegovy is the FDA-approved semaglutide formulation for chronic weight management. These are different approvals, different doses, and using one off-label for the other's indication has clinical implications your prescriber needs to weigh. Compounded semaglutide, widely available through telehealth platforms, is not equivalent to brand-name Ozempic or Wegovy and should be evaluated separately. A 100-pound loss is a legitimate possible outcome. It is not a guaranteed one, and the path there typically involves medical monitoring, not just a prescription and a prayer.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Tiff | MJ Journey · TikTok creator
464.6K views on this video
Any regrets?? Nope! #motivation #healthylifestyle #transformation #zempic #100gone
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about step 1 trial data (wilding et al., 2021, nejm): average?
STEP 1 trial data (Wilding et al., 2021, NEJM): average weight loss on semaglutide 2.4mg was 14.9% over 68 weeks, making a 100-pound loss possible but above average.
What does the video say about more than 70% of semaglutide users in clinical trials reported?
More than 70% of semaglutide users in clinical trials reported gastrointestinal side effects including nausea, vomiting, and diarrhea (Davies et al., 2021, Lancet).
What does the video say about weight regain after stopping semaglutide averages about two-thirds of lost?
Weight regain after stopping semaglutide averages about two-thirds of lost weight within one year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
What does the video say about ozempic (semaglutide 0.5mg-2mg)?
Ozempic (semaglutide 0.5mg-2mg) is FDA-approved for type 2 diabetes. Wegovy (semaglutide 2.4mg) is the approved formulation for chronic weight management. These are not interchangeable.
What does the video say about compounded semaglutide products?
Compounded semaglutide products are not FDA-approved and have not been shown to be equivalent in safety or efficacy to brand-name Ozempic or Wegovy.
What does the video say about transformation videos on tiktok disproportionately represent positive outcomes. survivorship bias?
Transformation videos on TikTok disproportionately represent positive outcomes. Survivorship bias means users with poor experiences, hospitalizations, or regain are less likely to post at 464,000 views.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Tiff | MJ Journey, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.